Program

DAY 1 - November 6, 2017
1:00 p.m.-3:00 p.m.

Educational Session 1: Genome Editing and its Clinical Application

Computational biology in translational cancer research
X. Shirley Liu, Dana-Farber Cancer Institute, Boston, MA

Domain-focused CRISPR screening
Christopher Vakoc, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY

High-throughput functional genomics: Coding, non-coding and beyond
Wensheng Wei, School of Life Sciences, Peking University, Beijing, China

3:15 p.m.-6:00 p.m.

Welcome and Keynote:  

Tumor suppressor and tumor maintenance genes
Scott W. Lowe, Memorial Sloan Kettering Cancer Center, New York, NY

Non-coding RNAs in cancer progression and clinical application
Hongyang Wang, Eastern Hepatobiliary Institute, Shanghai, China

6:00 p.m.-7:45 p.m.

Session 1: Tumor Evolution

Breast cancer intra-tumor heterogeneity landscapes: What, when and where
Carlos M. Caldas, Cancer Research UK Cambridge Institute, Cambridge, United Kingdom

Intratumoral heterogeneity and clonal selection of breast cancer
Zhiming Shao, Fudan University Shanghai Cancer Center, Shanghai, China

Heterogeneity in breast tumors: More than the sum of its parts
Kornelia Polyak, Dana-Farber Cancer Institute, Boston, MA

8:00 p.m.-10:00 p.m.

Opening Reception

DAY 2 - November 7, 2017
8:30 a.m.-10:30 a.m.

Session 2: Cancer Genomics

Cancer evolution as a therapeutic target
Alberto Bardelli, University of Turin, Candiolo, Italy

Talk title TBD
Huanming Yang, Beijing Genomics Institute, Beijing, China

Cancer evolution at single cell resolution
Sohrab Shah, BC Cancer Agency Vancouver Center, Vancouver, BC, Canada

10:30 a.m.-11:00 a.m. Tea Break
11:00 a.m.-1:00 p.m.

Session 3: Prevention

Notes from the field: Cancer prevention in rural China
Thomas W. Kensler, University of Pittsburgh, Pittsburgh, PA

Personalized cancer screening: Opportunities and challenges
Hongbing Shen,Nanjing Medical University, Nanjing, China

Aspirin and cancer: The promise of precision chemoprevention
Andrew T. Chan, Massachusetts General Hospital, Boston, MA

1:00 p.m.-3:30 p.m. Poster Session A with Lunch
3:30 p.m.-5:30 p.m.

Session 4: Metabolism

MYC and metabolic vulnerabilities of cancer
Chi Van Dang, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA

Talk title TBD
Amato J. Giaccia, Stanford University, Stanford, CA

Regulation of DNA Synthesis by APC/CCDH1
Shimin Zhao, Fudan University School of Life Sciences, Shanghai, China

DAY 3 - November 8, 2017
8:30 a.m.-10:30 a.m.

Session 5: TME and Inflammation
                                                                
Functional heterogeneity of the triple-negative breast cancer immune microenvironment
Morag Park, McGill University Goodman Cancer Center, QC, Canada

Systemic and microenvironmental determinants of cancer progression and metastasis
Sandra S. McAllister, Brigham and Women’s Hospital, Boston, MA

Modifying tumor microenvironment and immunity through tumor vessel normalization
Gou Young Koh, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Republic of Korea

10:30 a.m.-11:00 a.m. Tea Break
11:00 a.m.-1:00 p.m.

Session 6: Immunology

Innate immunity, inflammation and cancer: From bench to bedside
Alberto Mantovani, Humanitas University, Rozzano, Italy 

Anti-angiogenic conditioning of the tumor immune microenvironment
Michele De Palma, Swiss Federal Institute of Technology (EPFL), Lausanne, Switzerland

Cancer immunotherapy targeting Treg cells
Shimon Sakaguchi, Osaka University, Osaka, Japan

1:00 p.m.-3:30 p.m.

Poster Session B with Lunch

3:30 p.m.-5:30 p.m.

Session 7: Epigenetics

Targeting aberrant gene silencing in cancer
Jean-Pierre J. Issa, Fox Chase Cancer Center, Philadelphia, PA

HDAC inhibitors in solid tumors: Opportunities and challenges
Meiyu Geng, Chinese Academy of Sciences, Shanghai, China

Talk title TBD
James G. Herman, University of Pittsburgh Cancer Institute, Pittsburgh, PA

6:00 p.m.-7:30 p.m.

Professional Advancement Session

DAY 4 - November 9, 2017
8:30 a.m.-10:30 a.m. 

Educational Session 2: Clinical Trial Design

Precision medicine lessons from window-of-opportunity trials
Jennifer Rubin Grandis, UCSF, San Francisco, CA  

Talk title TBD
Edward Chu, University of Pittsburgh Cancer Institute, Pittsburgh, PA

Additional speaker to be announced

10:30 a.m.-11:00 a.m. Tea Break
11:00 a.m.-1:00 p.m.

Session 8: Precision Medicine

Digital pathology, liquid biopsy and the future of precision oncology
Mark S. Boguski, Inspirata, Inc., Tampa, FL

Talk title TBD
Carol R. Horowitz, Mount Sinai School of Medicine, New York, NY

Single-cell triple omics sequencing reveals genomic, epigenomic, and transcriptomic heterogeneity in human hepatocellular carcinomas and colorectal cancers
Fuchou Tang, Peking University, Beijing, China

1:00 p.m.-1:15 p.m.

Closing Remarks and Departure